BMY

$62.481.78%1.09

Nachbörslich: 62.55+0.07 +0.11%

Bristol Myers Squibb Co (BMY)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$61.39

Offen:

$63.00

24-Stunden-Volumen:

12,496,212

Relatives Volumen:

1.16

Marktkapitalisierung:

$127.71B

Einnahmen:

$48.48B

Nettoeinkommen (Verlust:

$7.27B

KGV:

17.54

EPS:

$3.56

Netto-Cashflow:

$11.91B

1W Leistung:

+1.63%

1M Leistung:

+0.13%

6M Leistung:

+3.12%

1Y Leistung:

+36.96%

1-Tages-Spanne:

$62.29$64.05

1-Wochen-Bereich:

$60.00$64.05

52-Wochen-Spanne:

$43.20$68.64

Bristol Myers Squibb Co Aktie (BMY) Unternehmensprofil

Firmenname

Bristol Myers Squibb Co

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(609) 252-4621

Adresse

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY, USA

Mitarbeiter

32,500

@BMSNEWS

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

BMY-Diskussionen auf X

BMY vs. LLY, JNJ, ABBV, MRK, NVS vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BMY Bristol Myers Squibb Co	$62.48	$127.71B	$48.48B	$7.27B	$11.91B	$3.56
LLY Lilly Eli Co	$1,417.54	$1.26T	$72.25B	$25.28B	$10.37B	$27.78
JNJ Johnson Johnson	$273.20	$657.68B	$97.93B	$21.04B	$17.80B	$8.63
ABBV Abbvie Inc	$294.89	$521.11B	$62.82B	$3.60B	$19.98B	$2.03
MRK Merck Co Inc	$149.52	$368.89B	$65.51B	$8.93B	$14.12B	$3.55
NVS Novartis Ag Adr	$160.79	$303.67B	$54.66B	$13.58B	$16.05B	$7.02

Bristol Myers Squibb Co Aktie (BMY) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-05	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-08-05	Hochstufung	Argus	Hold → Buy
2026-02-25	Eingeleitet	RBC Capital Mkts	Sector Perform
2026-02-20	Eingeleitet	Barclays	Overweight
2026-01-07	Hochstufung	UBS	Neutral → Buy
2025-12-15	Hochstufung	BofA Securities	Neutral → Buy
2025-12-12	Hochstufung	Guggenheim	Neutral → Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Perform
2025-08-05	Herabstufung	Daiwa Securities	Outperform → Neutral
2025-04-22	Eingeleitet	Cantor Fitzgerald	Neutral
2025-04-22	Eingeleitet	Piper Sandler	Overweight
2024-12-16	Hochstufung	Jefferies	Hold → Buy
2024-12-10	Resumed	BofA Securities	Neutral
2024-11-15	Eingeleitet	Wolfe Research	Peer Perform
2024-11-13	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-11-12	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-25	Herabstufung	Citigroup	Buy → Neutral
2024-10-17	Eingeleitet	Bernstein	Mkt Perform
2024-07-29	Herabstufung	Barclays	Overweight → Equal Weight
2024-03-11	Herabstufung	Societe Generale	Buy → Hold
2024-02-06	Herabstufung	Redburn Atlantic	Buy → Neutral
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-11-15	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-02	Herabstufung	Daiwa Securities	Outperform → Neutral
2023-10-27	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-10-27	Hochstufung	HSBC Securities	Reduce → Hold
2023-10-27	Herabstufung	William Blair	Outperform → Mkt Perform
2023-10-20	Resumed	UBS	Neutral
2023-07-14	Eingeleitet	HSBC Securities	Reduce
2023-07-10	Eingeleitet	SVB Securities	Market Perform
2023-06-28	Eingeleitet	Daiwa Securities	Outperform
2023-03-06	Eingeleitet	Jefferies	Hold
2023-01-17	Eingeleitet	Cantor Fitzgerald	Overweight
2022-11-18	Eingeleitet	Credit Suisse	Neutral
2022-10-10	Herabstufung	Guggenheim	Buy → Neutral
2022-09-14	Herabstufung	Berenberg	Buy → Hold
2022-06-03	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-04-06	Resumed	Morgan Stanley	Underweight
2021-12-17	Eingeleitet	Goldman	Buy
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-11-19	Eingeleitet	BMO Capital Markets	Outperform
2021-11-01	Herabstufung	Argus	Buy → Hold
2021-07-27	Resumed	Truist	Buy
2021-04-30	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-04-13	Hochstufung	Truist	Hold → Buy
2020-11-16	Hochstufung	Societe Generale	Hold → Buy
2020-11-10	Resumed	Bernstein	Mkt Perform
2020-11-06	Herabstufung	Gabelli & Co	Buy → Hold
2020-10-19	Hochstufung	Guggenheim	Neutral → Buy
2020-09-29	Eingeleitet	Berenberg	Buy
2020-07-28	Eingeleitet	Raymond James	Outperform
2020-04-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-23	Herabstufung	Societe Generale	Buy → Hold
2020-02-27	Eingeleitet	Barclays	Equal Weight
2020-01-06	Resumed	Citigroup	Buy
2019-12-13	Hochstufung	Argus	Hold → Buy
2019-11-22	Resumed	Morgan Stanley	Equal-Weight
2019-10-17	Resumed	BofA/Merrill	Buy
2019-08-14	Hochstufung	Atlantic Equities	Neutral → Overweight
2019-05-28	Eingeleitet	Goldman	Buy
2019-05-20	Herabstufung	Argus	Buy → Hold
2019-05-03	Hochstufung	Barclays	Equal Weight → Overweight
2019-05-03	Resumed	JP Morgan	Overweight
2019-01-15	Hochstufung	Societe Generale	Sell → Buy
2018-10-22	Herabstufung	Citigroup	Buy → Neutral

Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)

Umsatz

Nettogewinn

Free Cashflow

ENV

Bristol Myers Squibb Co-Aktie (BMY) Insiderhandel

Massacesi CristianSep 09 '26
EVP,Chief Med Offr,Head of Dev
Transaktion
Sale
Kosten
$64.57
#Aktien
6,249
Wert ($)
403,498
#Aktien Gesamt
18,748
Massacesi CristianSep 09 '26
Officer
Transaktion
Proposed Sale
Kosten
$64.57
#Aktien
6,249
Wert ($)
403,498
#Aktien Gesamt
0
Short Bartie WendySep 01 '26
EVP, Corporate Affairs
Transaktion
Option Exercise
Kosten
$66.92
#Aktien
1,236
Wert ($)
82,713
#Aktien Gesamt
13,317
Holzer Phil MAug 25 '26
Officer
Transaktion
Proposed Sale
Kosten
$67.50
#Aktien
500
Wert ($)
33,750
#Aktien Gesamt
0
Holzer Phil MAug 25 '26
SVP and Controller
Transaktion
Sale
Kosten
$67.50
#Aktien
500
Wert ($)
33,750
#Aktien Gesamt
16,862
Gallman CariAug 01 '26
EVP, General Counsel
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,061
Wert ($)
0
#Aktien Gesamt
14,192
Massacesi CristianAug 01 '26
EVP,Chief Med Offr,Head of Dev
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
51,172
Wert ($)
0
#Aktien Gesamt
51,172
Haller Julia AJun 15 '26
Director
Transaktion
Option Exercise
Kosten
$53.76
#Aktien
20,460
Wert ($)
1,099,930
#Aktien Gesamt
34,079
Short Bartie WendyJun 03 '26
EVP, Corporate Affairs
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
8,040
Wert ($)
0
#Aktien Gesamt
15,957
Lenkowsky AdamMay 01 '26
EVP, Chief Commercial Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,373
Wert ($)
0
#Aktien Gesamt
20,508

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Massacesi Cristian	EVP,Chief Med Offr,Head of Dev	Sep 09 '26	Sale	$64.57	6,249	403,498	18,748
Massacesi Cristian	Officer	Sep 09 '26	Proposed Sale	$64.57	6,249	403,498	0
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '26	Option Exercise	$66.92	1,236	82,713	13,317
Holzer Phil M	Officer	Aug 25 '26	Proposed Sale	$67.50	500	33,750	0
Holzer Phil M	SVP and Controller	Aug 25 '26	Sale	$67.50	500	33,750	16,862
Gallman Cari	EVP, General Counsel	Aug 01 '26	Option Exercise	$0.00	1,061	0	14,192
Massacesi Cristian	EVP,Chief Med Offr,Head of Dev	Aug 01 '26	Option Exercise	$0.00	51,172	0	51,172
Haller Julia A	Director	Jun 15 '26	Option Exercise	$53.76	20,460	1,099,930	34,079
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '26	Option Exercise	$0.00	8,040	0	15,957
Lenkowsky Adam	EVP, Chief Commercial Officer	May 01 '26	Option Exercise	$0.00	1,373	0	20,508

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

Oct 30, 2026

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress - Zacks Investment Research

Oct 30, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 30, 2026

BofA raises Bristol-Myers Squibb stock price target to $67 - Investing.com

Oct 30, 2026

How Bristol Myers’s CEO Challenged the Company’s Managers - WSJ

Oct 30, 2026

Is Bristol-Myers Squibb (BMY) Stock Cheap, Or Are Risks Priced In? - Simply Wall St

Oct 30, 2026

Wells Fargo cuts Bristol-Myers Squibb stock price target on LOE concerns - Investing.com Canada

Oct 30, 2026

Truist reiterates Buy on Bristol-Myers Squibb stock on Q3 beat By Investing.com - Investing.com Canada

Oct 30, 2026

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance Singapore

Oct 29, 2026

Bristol-Myers Squibb Co (BRM.HM) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance UK

Oct 29, 2026

Bristol-Myers Squibb Company (BMY) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

BMS Aims To Build Confidence In Pipeline As Growth Portfolio Sees Gains - Scrip

Oct 29, 2026

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Oct 29, 2026